Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
Latest Information Update: 14 Jan 2025
At a glance
- Drugs Recaticimab (Primary)
- Indications Hypercholesterolaemia; Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 08 Aug 2022 Status changed from recruiting to completed.
- 15 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 New trial record